节点文献

阿苯达唑市场调查分析

Market Research and Analysis of Albendazole

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 朱振国郑荣远杨学志殷为勇

【Author】 ZHU Zhenguo,ZHENG Rongyuan,YANG Xuezhi,YIN Weiyong(Dept.of Neurology,The First Affiliated Hospital of Wenzhou Medical College,Wenzhou 325000,China)

【机构】 温州医学院附属第一医院神经科

【摘要】 目的:为临床合理、安全应用阿苯达唑提供参考。方法:通过搜索引擎及国内、外各医药网站、数据库,对阿苯达唑的研发情况、市场信息、适应证等情况进行分析。结果与结论:目前阿苯达唑有片剂、胶囊剂、颗粒剂、口服液、糖浆剂5种剂型;近几年其在国内销售额基本列居抗寄生虫药的前3位,生产厂家国内达39家;可用于治疗21种人体寄生虫病。阿苯达唑临床使用广泛,但是引发少见的脑炎综合征、过敏性休克等严重不良反应隐藏着治疗风险,须加强管理。

【Abstract】 OBJECTIVE: To provide information for clinical rational and safe use of albendazole.METHODS: The medical database and network both at home and abroad were searched and the data regarding the research and development,the market information and indications of albendazole were analyzed.RESULTS & CONCLUSIONS: 5 dosage forms of albendazole are available in the market: tablets,capsules,granules,oral liquid,and syrup.The sales amount of albendazole in recent years dominated the first 3 places in domestic antiparasites market.There are a total of 39 domestic manufactures for albendazole,which can be used to treat 21 kinds of human parasitosis.Its clinical application is widespread.However,severe adverse drug reactions such as the rare encephalitis syndrome and allergic shock etc induced by albendazole pose hidden risks for treatment;therefore,management on its use should be strengthened.

【基金】 国家食品药品监督管理局药品评价中心资助项目
  • 【分类号】R978;F426.72
  • 【被引频次】10
  • 【下载频次】552
节点文献中: 

本文链接的文献网络图示:

本文的引文网络